Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - ViroLogic, Inc. (NasdaqNM:VLGC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  7Conference call: Virologic Inc. Earnings (Q2 2001)
Aug  7Earnings Announcement
Location
270 East Grand Avenue
South San Francisco, CA 94080
Phone: (650) 635-1100
Fax: (650) 635-1111
Email: sho@virologic.com
Employees (last reported count): 159
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 43%
·Over the last 6 months:
 · 5 insider buys; 14.0K shares (0.2% of insider shares)
·Institutional: 38% (66% of float)
(28 institutions)
·Net Inst. Selling: 278.0K shares (+3.84%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
ViroLogic, Inc., a biotechnology company, is engaged in developing, marketing and selling products to guide and improve treatment of viral diseases. The Company developed PhenoSense, a proprietary technology designed to directly measure the impact of genetic mutations on drug resistance and use this information to guide therapy. PhenoSense has been utilized in testing drug resistance in viruses that cause serious viral diseases, such as AIDS, hepatitis B and hepatitis C. The Company's first product, PhenoSense HIV, is a test that directly and quantitatively measures resistance of a patient's HIV to anti-viral drugs. The results help physicians select appropriate drugs for their HIV patients. ViroLogic is also developing PhenoSense products for other serious viral diseases, and is collecting PhenoSense test results and related clinical data in an interactive database, which the Company plans to make available to physicians for use in therapy guidance.
More from Market Guide: Expanded Business Description

Financial Summary
ViroLogic, Inc. is a biotechnology company developing and marketing products to guide and improve treatment of viral diseases, utilizing a method of directly measuring the impact of genetic mutations on drug resistance. For the six months ended 6/30/01, revenue totaled $7.9 million, up from $2.8 million. Net loss applicable to Common fell 51% to $12.9 million. Results reflect growth in the patient testing business, partially offset by higher marketing expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

William Young, 56
Chairman, Pres, CEO
$360K--  
Karen Wilson, 37
CFO, VP
--  --  
Frank Barker, 58
VP, Information Technology and CIO
224K--  
Robin Toft, 40
VP of Sales and Marketing
215K$196K
Patricia Wray, 44
VP of HR
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VLGCAs of 31-Aug-2001
Price and Volume
52-Week Low
on 15-Mar-2001
$1.00 
Recent Price$2.18 
52-Week High
on 14-Sep-2000
$23.00 
Daily Volume (3-month avg)193.3K
Daily Volume (10-day avg)49.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-89.4%
52-Week Change
relative to S&P500
-85.8%
Share-Related Items
Market Capitalization$43.7M
Shares Outstanding20.0M
Float11.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.10 
Earnings (ttm)-$1.29 
Earnings (mrq)-$0.29 
Sales (ttm)$0.63 
Cash (mrq)$0.61 
Valuation Ratios
Price/Book (mrq)1.97 
Price/EarningsN/A 
Price/Sales (ttm)3.47 
Income Statements
Sales (ttm)$12.5M
EBITDA (ttm)-$24.7M
Income available to common (ttm)-$25.6M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-60.34%
Return on Equity (ttm)-77.49%
Financial Strength
Current Ratio (mrq)2.12 
Debt/Equity (mrq)0.17 
Total Cash (mrq)$12.3M
Short Interest
As of 8-Aug-2001
Shares Short131.0K
Percent of Float1.1%
Shares Short
(Prior Month)
261.0K
Short Ratio1.35 
Daily Volume97.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Some event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.